Could dropping one drug make stem cell transplants safer?
NCT ID NCT05256537
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This study looks at whether it is safe to remove one immune-suppressing drug, mycophenolate mofetil (MMF), from the standard treatment plan after a stem cell transplant for blood cancers. Sixty adults aged 18 to 75 will receive the transplant without MMF and be monitored for up to two years. The main goal is to see if the donated stem cells still grow properly without this drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood cancer patients may need higher antibiotic doses to beat superbugs
- New antibody may offer safer shield against transplant complications
- Could a 30-Day habit shift help blood cancer patients regain control?
- Experimental blood cancer drug KK2430 enters first human tests
- New hope for tough blood cancers? early trial launches
- AI translates doctor speak for cancer patients